null
...
Skin cancer trials. Time to celebrate brehs 
?
The world's first personalised mRNA jab for melanoma is being trialled on British patients in what has been hailed a potential 'gamechanger' for cancer treatment.
The vaccine is custom-built for individuals using the specific genetic makeup of their tumour – giving it the best chance of a cure.
It works by telling the body to hunt down cancer cells and prevent the deadly disease from coming back.
Early results of the jab – developed by pharma giants Moderna and MSD – found it drastically improved the survival chances of the deadliest form of skin cancer.
Now University College London Hospitals NHS Foundation Trust (UCLH) is now leading the final phase of trials of the therapy, which scientists hope could also be used to stop lung, bladder and kidney cancer.
The new jab, which is set to be tested on around 1,100 patients worldwide, is an individualised neoantigen therapy (INT) and is sometimes referred to as a cancer vaccine.
It is designed to trigger the immune system so it can fight back against the patient's specific type of cancer and tumour.
Known as mRNA-4157 (V940), it targets tumour neoantigens, which are expressed by tumours and are individual to each patient.
These markers on the tumour can potentially be recognised by the immune system.
The jab carries coding for up to 34 neoantigens and activates an anti-tumour immune response based on the unique mutations in a patient's cancer.
www.dailymail.co.uk
www.medscape.com
www.mskcc.org
?'Game-changer' cancer jab offers hope of a cure: NHS launches trial of world's first personalised vaccine to destroy melanomas - and it uses same tech as pioneering Covid shots
The world's first personalised mRNA jab for melanoma is being trialled on British patients in what has been hailed a potential 'gamechanger' for cancer treatment.
The vaccine is custom-built for individuals using the specific genetic makeup of their tumour – giving it the best chance of a cure.
It works by telling the body to hunt down cancer cells and prevent the deadly disease from coming back.
Early results of the jab – developed by pharma giants Moderna and MSD – found it drastically improved the survival chances of the deadliest form of skin cancer.
Now University College London Hospitals NHS Foundation Trust (UCLH) is now leading the final phase of trials of the therapy, which scientists hope could also be used to stop lung, bladder and kidney cancer.
The new jab, which is set to be tested on around 1,100 patients worldwide, is an individualised neoantigen therapy (INT) and is sometimes referred to as a cancer vaccine.
It is designed to trigger the immune system so it can fight back against the patient's specific type of cancer and tumour.
Known as mRNA-4157 (V940), it targets tumour neoantigens, which are expressed by tumours and are individual to each patient.
These markers on the tumour can potentially be recognised by the immune system.
The jab carries coding for up to 34 neoantigens and activates an anti-tumour immune response based on the unique mutations in a patient's cancer.
'Game-changing' cancer vaccine offers hope of a cure
The vaccine is custom-built for individuals using the specific genetic makeup of their tumour - telling the body to hunt down cancer cells and prevent the deadly disease from coming back.
Coming Soon: The First mRNA Vaccine for Melanoma?
Results of a phase 2b trial were favorable, and Moderna suggests that an mRNA vaccine for melanoma could be available in 2025.
www.medscape.com
Investigational mRNA Vaccine Induced Persistent Immune Response in Phase 1 Trial of Patients With Pancreatic Cancer
Learn how MSK researchers are deploying mRNA vaccines against pancreatic cancer.
www.mskcc.org
